BioSpace News Archive

Business

Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the voluntary withdrawal of the supplemental Biologics License Application (sBLA) for Libtayo ® (cemiplimab-rwlc) as a second-line treatment for patients with advanced cervical cancer.

January 28, 2022
·
18 min read
Pharm Country

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B.

January 28, 2022
·
17 min read
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Alterity Therapeutics today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson’s Disease. MSA is a devastating neurodegenerative disorder without approved therapy.

January 28, 2022
·
7 min read
Business

HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors

HTG Molecular Diagnostics, Inc. announced it has appointed biopharmaceutical industry veteran Christopher Kiritsy to its Board of Directors.

January 28, 2022
·
4 min read
Biotech Beach

FDA Accepts Label Update for Plasma IQ™, the First FDA-Cleared Handheld Plasma Energy Device

Suneva Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted updates to the Plasma IQ ™ label, including the removal of the product’s eye contraindication.

January 28, 2022
·
10 min read
Biotech Beach

Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays.

January 28, 2022
·
6 min read
I Peace’s Cell Manufacturing Facility “Peace Engine Kyoto” now registered as U.S. FDA Drug Establishment

The registration recognizes I Peace’s cell manufacturing facility as suitable for drug manufacturing, based on detailed information submitted to the FDA.

January 28, 2022
·
3 min read
Business

CARRA Appoints Larry Hausner as Interim CEO

Childhood Arthritis and Rheumatology Research Alliance (CARRA) announced its appointment of Larry Hausner as interim chief executive officer, effective today.

January 28, 2022
·
2 min read
BioMidwest

Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark Office

Nutriband Inc. announced the receipt of an Issue Notification from the United States Patent and Trademark Office for its United States patent entitled, “Abuse and Misuse Deterrent Transdermal System,” that protects its AVERSA™ transdermal abuse deterrent technology.

January 28, 2022
·
4 min read
Business

Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

Advaxis, Inc today announced that the Company entered into an agreement with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock.

January 28, 2022
·
5 min read